Skip to main content
Clinical Trials/NCT03276923
NCT03276923
Recruiting
Not Applicable

Maternal Autoimmune Disease Research Alliance (MADRA) Registry

Duke University2 sites in 1 country1,000 target enrollmentJanuary 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Autoimmune Diseases
Sponsor
Duke University
Enrollment
1000
Locations
2
Primary Endpoint
Risk factors associated with poor pregnancy outcomes as measured by the MADRA-DAP questionnaire.
Status
Recruiting
Last Updated
3 months ago

Overview

Brief Summary

This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases.

The main goal of MADRA is to identify ways to improve the health of women with rheumatic diseases and their babies during pregnancy.

Prior studies demonstrate the importance of increase inflammation prior to and during pregnancy on these outcomes. The future research will seek to better define these risk factors and to identify ways to may improve them.

Detailed Description

At each site, the patients will be under the care of the participating rheumatologist and their local obstetrician during the pregnancy. This is a natural-history study and will not include medications, laboratory testing, or procedures outside of the standard of care. Management of the rheumatologic disease will be directed based on patient needs by the local rheumatologist and obstetrician. Enrollment in the registry will not dictate specific therapy. The Registry will include data from each office visit during pregnancy and up to 12 months after delivery. The registry will be ongoing, with periodic analysis of clinical data samples as specific studies are approved. Enrollment in the registry does not significantly increase risks for a patient.

Registry
clinicaltrials.gov
Start Date
January 1, 2018
End Date
January 1, 2027
Last Updated
3 months ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Desire for pregnancy within 6 months or currently pregnant
  • Women with systemic autoimmune disease, including:
  • Lupus (systemic lupus erythematosus or cutaneous lupus)
  • Antiphospholipid Syndrome or positive antiphospholipid antibodies
  • Rheumatoid Arthritis
  • Scleroderma (systemic sclerosis)
  • Sjogren's Syndrome
  • Inflammatory Arthritis (including Psoriatic Arthritis and Ankylosing Spondylitis)
  • Undifferentiated Connective Tissue Disease (UCTD)
  • Vasculitis

Exclusion Criteria

  • Unable to speak English
  • Unable to provide informed consent
  • Unable to travel to Duke University for follow-up visits

Outcomes

Primary Outcomes

Risk factors associated with poor pregnancy outcomes as measured by the MADRA-DAP questionnaire.

Time Frame: up to 10 years

The investigators will ask the participants questions from the MADRA-DAP questionnaire to determine poor pregnancy outcomes.

Study Sites (2)

Loading locations...

Similar Trials